Drug Profile
Follitropin alfa/lutropin alfa
Alternative Names: Lutropin alfa/follitropin alfa; Pergoveris; Recombinant human follicle stimulating hormone/luteinising hormone; rh-FSH/LHLatest Information Update: 21 Jun 2022
Price :
$50
*
At a glance
- Originator Serono Europe
- Developer Merck KGaA; Merck Serono Co Ltd; Serono Europe
- Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
- Mechanism of Action Luteinising hormone stimulants; Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Female infertility
Most Recent Events
- 28 May 2022 Merck KGaA completes a phase-I trial in Female infertility in China (SC) (NCT04899193)
- 08 May 2021 Phase-I clinical trials in Female infertility in China (SC) (NCT04899193)
- 31 Aug 2018 Discontinued - Phase-III for Female infertility (Combination therapy) in United Kingdom, Latvia, Hungary, Germany, Czech Republic, Estonia, Sweden, Belgium, Netherlands, Denmark, Spain, Poland, Finland (SC)